I’m a retired physician with no experience in co
Post# of 157776
(Total Views: 350)
Posted On: 10/08/2025 8:24:55 PM
I’m a retired physician with no experience in corporate finance….. but regarding the companies recent request to increase our outstanding shares from175,000,000,000 to 225,000,000,000… I have voted yes. Here’s why.
I believe we already have 175,000,000 unissued shelf shares…so why the need for another 500,000,000? For the company to issue as needed for ongoing expenses or our pending phase 2 TNBC study? As they struggle to go it alone. Maybe. The company would be selling at low market prices or below market price to selected Investors. This just doesn’t make sense to me.
With all that Cytodyn has learned about Leronlimab and how it works with checkpoint inhibitors like Keytruda, upgrading PDL1 and turning cold tumors hot, and considering that patent will be expiring soon, Merck may only need a little encouragement, a little more prospective data from the CRC trial, or a 6th or a 7th, 8,9, or10th TNBC lady from compassionate use, as Jay recently told us he has, to convince a partner (Merck) to act. That data is being accrued now.That makes sense to me.
Merck would reasonably want at least 1/3 ownership before partnering. Our new total shares available would total 675,000,000… only 50 million from 1/3 ownership. If a partner (Merck) already owns over 50 million, (well below, the 5% required for reporting to the FTC) and buys these new shares….with an option to sometime in the future acquire controlling interest in CYDY….I believe….Well …hello MERCK…our new partner before Christmas or Easter!!!
Or am I just a dreaming old fool?
Regards,
Smokeandmist
I believe we already have 175,000,000 unissued shelf shares…so why the need for another 500,000,000? For the company to issue as needed for ongoing expenses or our pending phase 2 TNBC study? As they struggle to go it alone. Maybe. The company would be selling at low market prices or below market price to selected Investors. This just doesn’t make sense to me.
With all that Cytodyn has learned about Leronlimab and how it works with checkpoint inhibitors like Keytruda, upgrading PDL1 and turning cold tumors hot, and considering that patent will be expiring soon, Merck may only need a little encouragement, a little more prospective data from the CRC trial, or a 6th or a 7th, 8,9, or10th TNBC lady from compassionate use, as Jay recently told us he has, to convince a partner (Merck) to act. That data is being accrued now.That makes sense to me.
Merck would reasonably want at least 1/3 ownership before partnering. Our new total shares available would total 675,000,000… only 50 million from 1/3 ownership. If a partner (Merck) already owns over 50 million, (well below, the 5% required for reporting to the FTC) and buys these new shares….with an option to sometime in the future acquire controlling interest in CYDY….I believe….Well …hello MERCK…our new partner before Christmas or Easter!!!
Or am I just a dreaming old fool?
Regards,
Smokeandmist
(10)
(0)